Funding backs next phase of avian metapneumovirus vaccine work
Bottom line
The Foundation for Food & Agriculture Research, South Dakota State University, and the U.S. Poultry & Egg Association are putting $250,000 behind avian metapneumovirus vaccine work aimed at protecting U.S. chickens and turkeys. FFAR lists the 2026 Rapid Outcomes from Agricultural Research award as a $125,000 grant matched to reach a $250,000 total for a project focused on evaluating imported commercial vaccines and advancing a live attenuated vaccine based on U.S. strains. The funding builds on South Dakota State’s earlier work identifying the fast-moving aMPV A and B outbreaks that emerged in U.S. poultry in late 2023 and early 2024, and on more recent reports that its team has already developed live and inactivated subtype B vaccine candidates. (foundationfar.org)
Why it matters: For veterinary professionals working with poultry systems, this is a sign that the field is moving from outbreak detection and emergency response toward more tailored prevention tools. USDA’s Center for Veterinary Biologics has already been accepting applications tied to aMPV products, including certain imported developmental materials, and APHIS says emergency import pathways and experimental approaches are in play while longer-term products are developed. A U.S.-strain vaccine could matter because aMPV A and B spread quickly across major production regions, and researchers and industry groups are now focused on matching protection more closely to the viruses circulating domestically. (content.govdelivery.com)
What to watch: Watch for efficacy data on imported vaccines, field-trial results for SDSU’s candidates, and any movement from emergency or experimental use toward USDA-licensed commercial products. (sdstate.edu)
Key facts
- Funding
- $250,000 total
- FFAR share
- $125,000 grant
- Lead institution
- South Dakota State University
- Partner
- U.S. Poultry & Egg Association
- Project focus
- Evaluate imported commercial vaccines and advance a live attenuated vaccine
- Vaccine basis
- U.S. strains
- Disease
- Avian metapneumovirus
- Outbreak timing
- Late 2023 and early 2024
A new $250,000 research push is aimed at speeding avian metapneumovirus vaccine options for U.S. poultry. The Foundation for Food & Agriculture Research’s 2026 Rapid Outcomes from Agricultural Research program lists a Brookings, South Dakota-based project led by South Dakota State University, with matching support from the U.S. Poultry & Egg Association, to evaluate imported commercial vaccines and advance a live attenuated vaccine built from U.S. strains. FFAR’s share is $125,000, bringing the total to $250,000. (foundationfar.org)
The funding arrives after aMPV subtypes A and B were detected in U.S. poultry in late 2023 and early 2024, marking a major shift in the domestic disease picture. South Dakota State researchers were among the first to characterize the outbreaks, and published work described severe respiratory disease affecting turkey and chicken farms across multiple states in early 2024. More recent surveillance and genomic studies indicate those subtypes spread rapidly through major poultry-producing regions, with subtype patterns varying by geography. (pmc.ncbi.nlm.nih.gov)
What’s changed is that the conversation is no longer only about detection and biosecurity. It’s now also about product development and regulatory pathways. According to FFAR, the newly funded project is specifically designed to do two things at once: assess imported commercial vaccines and move forward a U.S.-strain live attenuated candidate. That matters because the U.S. industry has been relying on interim measures while domestic solutions catch up. USDA APHIS’ Center for Veterinary Biologics says it has been accepting certain aMPV-related applications, including imported developmental materials and experimental autogenous products, and its January 13, 2026 Q&A says limited purity and safety testing was performed on the first serial of modified live viral vaccines to assess import eligibility. (foundationfar.org)
South Dakota State’s own updates suggest the science is moving quickly. In June 2026, the university said its Animal Disease Research and Diagnostic Laboratory had developed both live and killed vaccine candidates for aMPV subtype B after roughly two years of work. The team reported safety and efficacy signals in commercial turkeys and said future experimental testing and field trials would help confirm performance, including on subtype A. Separately, USPOULTRY announced in May 2026 the completion of a research project developing live and inactivated subtype B candidates, underscoring that this latest funding is part of a broader, continuing effort rather than a standalone announcement. (sdstate.edu)
Industry and expert commentary points to both urgency and caution. In the SDSU release, Sunil Mor said emerging aMPV A and B strains are causing major economic losses and that the team is trying to deliver the first vaccine based on a U.S. field strain. At the same time, USDA-linked and review literature show why the sector is proceeding carefully: emergency imports and experimental autogenous approaches may help fill immediate gaps, but live vaccines raise familiar questions around safety, stability, and how to distinguish vaccine from wild-type virus in surveillance. USDA Agricultural Research Service project materials and 2026 poultry science abstracts both reflect that concern. (sdstate.edu)
Why it matters: For veterinarians and animal health teams serving poultry operations, this funding signals a more structured transition from outbreak management to vaccine strategy. A U.S.-strain product could improve antigenic fit if currently circulating domestic viruses differ meaningfully from legacy or foreign vaccine strains, though that inference will need to be proven in controlled studies. It also suggests more demand ahead for veterinary input on flock-level vaccination protocols, field monitoring, differential diagnosis, and interpretation of surveillance results in vaccinated populations. In practical terms, the work sits at the intersection of pharmacology, diagnostics, and production medicine: the value of any vaccine won’t just depend on efficacy, but on route of administration, compatibility with commercial systems, regulatory status, and whether it supports cleaner disease tracking. (foundationfar.org)
What to watch: The next milestones are likely to be challenge data on imported products, field-trial readouts for SDSU’s candidates, and eventual movement through USDA’s biologics pathway toward licensed products that can be used beyond emergency or experimental frameworks. (aphis.usda.gov)